Idelalisib has presented serious adverse events in combination trials in both the US and Europe.
Following reports of an increased rate of adverse events (AEs), including deaths, in clinical trials that include the use of idelalisib (Zydelig) in combination with other cancer medicines, the FDA has alerted healthcare providers, and is reviewing the trial findings. The drug’s developer, Gilead Sciences, Inc, will be halting 6 clinical trials in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and indolent non-Hodgkin lymphomas (NHL).
Zydelig is currently approved by the FDA for the treatment of:
The drug is also being reviewed by the European Medicine Agency (EMA) following reports of increased rate of serious AEs, primarily due to infections, in trials that were evaluating idelalisib in combination with other cancer drugs. The EMA has asked that patients be closely monitored, and treatment should continue if patients tolerate the drug.
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Bimekizumab Shows Sustained Efficacy in Treating Axial Spondyloarthritis for 52 Weeks
April 30th 2024Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.
Read More